Abstract
A Phase II study was performed to investigate the efficacy and tolerability of paclitaxel and ifosfamide chemotherapy for the treatment of anthracycline-resistant metastatic breast carcinoma (MBC). Recurrent or progressed MBC within 12 months after anthracycline-based chemotherapy was defined as anthracycline-resistant. A 24-hour infusion of paclitaxel (175 mg/m(2)) on Day 1 and subsequent infusions of ifosfamide (1.8 g/m(2)/day) with mesna (360 mg/m(2)/day) on Days 2- 4, were performed every 3 weeks. Twenty-one patients were eligible for toxicity analysis. Response rate and survival duration were evaluated in 21 patients. Frontline chemotherapy was the FAC (5-fluorouracil, doxorubicin, cyclophosphamide) regimen in all patients. Objective response was found in 9 patients (42.9%), including complete response in 3 (13.4%). Median response duration and median survival duration were 10 months (range, 2-24+) and 19+ months (range, 2-32+), respectively. Sixteen (76%) experienced Grade 3/4 leukopenia controllable with granulocyte macrophage colony-stimulating factor. Other significant toxicities were peripheral neuropathy (n = 3), mucositis (n = 2), and liver dysfunction (n = 1). However, there was no chemotherapy-related death. Pacli...Continue Reading
References
Sep 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P PetersJ O Moore
May 5, 1971·Journal of the American Chemical Society·M C WaniA T McPhail
May 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A D SeidmanP Forsythe
Aug 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S AbramsM A Friedman
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J CrownL Norton
Aug 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W H WilsonJ O'Shaughnessy
Nov 5, 1994·Lancet·K Gelmon
Oct 1, 1993·Cancer Treatment Reviews·R PazdurM N Raber
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M NabholtzB Winograd
Mar 1, 1996·Cancer Treatment Reviews·S A JohnsonP Pouillart
Aug 1, 1997·Breast Cancer Research and Treatment·A M MuradG Schwartsmann
Feb 6, 1998·Cancer·C A BunnellL N Shulman
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M ClemonsA Howell
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G FountzilasD Skarlos
May 30, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U KlaassenS Seeber
Jun 13, 1998·Anti-cancer Drugs·U KlaassenS Seeber
Aug 26, 1998·American Journal of Clinical Oncology·R S WaltersG N Hortobagyi
Nov 2, 1999·Cancer Treatment Reviews·N KrögerA R Zander
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R E SmithM P Thirlwell
Citations
Dec 17, 2009·Cancer Chemotherapy and Pharmacology·Yong Wha MoonJoo-Hang Kim
Mar 8, 2014·Inorganic Chemistry·Linhong ZhaoYangzhong Liu
Jan 6, 2006·Drug Metabolism Reviews·Jing ZhangYi-Zhun Zhu
Feb 3, 2016·F1000Research·Martin L AshdownBrendon J Coventry